Insmed | INSM - Cost Of Sales


Insmed reported $29.34M in Cost of Sales for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 2.48B
Cash and Equivalent USD 1.28B
Cost of Sales USD 29.34M
Current Assets USD 2.08B
Current Liabilities USD 311.68M
Debt USD 564.1M
EBIT USD -253.88M
EBITDA USD -297.13M
Employees 1.27K
EPS Earnings Per Share USD -1.7
Equity Capital and Reserves USD 1.25B
Gross Profit on Sales USD 78.08M
Interest Expense on Debt USD 21.25M
Interest Income USD 0
Loan Capital USD 560.95M
Market Capitalization USD 21.64B
Net Income USD -321.69M
Operating Expenses USD 361.29M
Operating Profit USD -253.88M
Ordinary Share Capital USD 211.11M
Pre-Tax Profit USD -320.44M
Sales Revenues USD 107.4M
Selling and Administration Expenses USD 76.44M
Stock USD 107.61M
Trade Creditors USD 78.35M
Trade Debtors USD 55.03M

Cost Of Sales Change Date
BioMarin Pharmaceutical USD 154.94M 3.38M Jun/2025
Cytokinetics USD 112.55M 12.71M Jun/2025
Dynavax Technologies USD 14.04M 13.5M Jun/2025
Gilead Sciences USD 1.5B 39M Jun/2025
Insmed USD 29.34M 8.06M Jun/2025
Novartis USD 3.32B 5M Jun/2025
Regeneron Pharmaceuticals USD 530.2M 264.7M Jun/2025
Sarepta Therapeutics USD 153.22M 15.66M Jun/2025
Ultragenyx Pharmaceutical USD 23M 5.66M Jun/2025
Vertex Pharmaceuticals USD 407.5M 44.5M Jun/2025